Walleye Capital
CYCN icon

Walleye Capital’s Cyclerion Therapeutics CYCN Stock Holding History

Walleye Capital’s Portfolio CYCN Stock Details CYCN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-1,267
Closed -$44K – 2350
2021
Q4 		$44K Buy
+1,267
New +$59.9K ﹤0.01% 1790
2021
Q2 		– Sell
-750
Closed -$42 – 1372
2021
Q1 		$42 Buy
+750
New +$56.3K ﹤0.01% 1072

Other funds holding CYCN

SPC
Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return
MP
MFN Partners Boston, Massachusetts $4.77B AUM 72.29% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PVI
Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

Walleye Capital's CYCN Position: Q1 2022 in Review

Walleye Capital sold out of Cyclerion Therapeutics (CYCN) in Q1 2022, closing a stake of 1,267 shares — an estimated $44K sold.

Walleye Capital first reported a position in CYCN in Q1 2021 and held it in 2 quarters. The position peaked at $44K in Q4 2021. 50 funds tracked by Wall St. Rank hold CYCN as of Q1 2022.

  • Walleye Capital reported no remaining Cyclerion Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Walleye Capital sold 1,267 Cyclerion Therapeutics shares in Q1 2022, an estimated $44K.
  • Walleye Capital first reported a position in Cyclerion Therapeutics in Q1 2021 and held it in 2 quarters.
  • Walleye Capital's Cyclerion Therapeutics position peaked at $44K in Q4 2021.
  • 50 funds tracked by Wall St. Rank held Cyclerion Therapeutics as of Q1 2022.

Based on Walleye Capital's 13F filing for Q1 2022, filed 16 May 2022.